Hemophilia A and VWD dosing – save with ALPHANATE: 1 vial for 2 indications

ALPHANATE offers convenient dosing for patients with hemophilia A:

  • In the hospital for surgery or breakthrough bleeding1
  • For use in adult and pediatric patients1
  • Trusted treatment for more than 20 years1
  • Since launch in 1997, there has never been a confirmed case of prion or virus transmission

Learn about hemophilia A dosing

ALPHANATE offers convenient dosing for patients with von Willebrand disease (VWD):

  • For preoperative, periprocedural, and postoperative maintenance1
  • For use in adult and pediatric patients1
  • A maximum infusion rate of 10 mL/min1
  • 5 vial sizes for a variety of dosing options1

Learn about von Willebrand disease dosing 

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

ALPHANATE Dosing and Cost Calculator

Welcome to a convenient tool that allows you to perform a cost analysis of your coagulation factors. As you use this calculator, you will find that factor products can differ in both in vivo recovery and pricing structure, which is why you need a calculator specifically tailored to this type of product evaluation. The instructions below explain how to perform a complete evaluation.

Select One of the Following to Start Calculating

 
Alphanate Factors for Health Program

von Willebrand disease

 

 
Alphanate Managing Bleeding Disorders

Hemophilia A

 

 
Grifols Gear Travel Kit

Hemophilia B

 

 

Example pricing comparison for treatment of VWD*

List price VWF:RCo : FVIII Price per VWF:RCo IU
ALPHANATE $0.75/ FVIII IU 1.3:1 $0.58
Competitor $0.75/VWF:RCo IU $0.75
ALPHANATE
List price $0.75/ FVIII IU
VWF:RCo : FVIII 1.3:1
Price per VWF:RCo IU $0.58
Competitor
List price $0.75/VWF:RCo IU
VWF:RCo : FVIII
Price per VWF:RCo IU $0.75

Make the most of ALPHANATE treatment

The value of ALPHANATE

Download an educational booklet demonstrating the value of ALPHANATE in both hemophilia A and VWD patients.
Download PDF


Optimizing treatment with WAPPS-Hemo

Discover how WAPPS-Hemo can help you optimize care for your hemophilia A patients.
Learn more


Have any questions?

Our specialty sales representative assigned to your territory will be glad to contact or visit you to answer any questions about ALPHANATE.
Request a representative


Indications and Important Safety Information

ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human])

ALPHANATE is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

 

AlphaNine® SD (coagulation factor IX [human])

AlphaNine is indicated for the prevention and control of bleeding in patients with factor IX deficiency due to hemophilia B.

AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of factor IX complex concentrates which contain high amounts of factor II, VII and X. AlphaNine SD contains low, nontherapeutic levels of factor II, VII and X.

Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.

Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.

Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to factor IX.

In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.

AlphaNine SD should not be administered at a rate exceeding 10 mL/minute. Rapid administration may result in vasomotor reactions.

Please see full Prescribing Information for AlphaNine SD.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.

Reference:

  1. ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) Prescribing Information. Grifols.